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Supplemental
Medical condition or disease under investigation
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Purpose of clinical trial
To assess whether intradermal injections of self-inactivating (SIN) lentiviral vector (LV)-mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1 (investigational medicinal product -IMP), are safe and have potential efficacy in adults with RDEB.
Primary objective
To evaluate the safety of intradermal injections of SIN LV-mediated COL7A1 gene-modified autologous fibroblasts in adults with RDEB.
Secondary objectives
1. To evaluate the potential efficacy of intradermal injections of SIN LV-mediated COL7A1 gene-modified autologous fibroblasts in adults with RDEB at week (W) 2, month (M) 3 and M12 after the IMP injections. 2. To evaluate the immune response against the recombinant type VII collagen (C7) at W2, W4, M3, M6 and M12 after the IMP injections compared to baseline.
Trial Design
Phase 1, non-randomized, open-label, single-center, proof-of-concept study.
Endpoints Primary Endpoints
• Adverse events (AEs), Serious Adverse Events (SAEs), Adverse Reactions (ARs) and Serious Adverse Reactions (SARs) at each visit over a 12-month follow-up period.
Secondary Endpoints
• Skin biopsy analysis of treated skin at W2, M3 and M12 compared to untreated skin: I.
C7 protein expression by immunofluorescence microscopy (IF) II.
Morphology of anchoring fibrils at the dermal-epidermal junction (DEJ) by transmission electron microscopy (TEM) III.
Vector copy number by quantitative polymerase chain reaction (qPCR) • Serum analysis for: IV.
Detection of anti-C7 antibodies by enzyme-linked immunosorbent assay (ELISA) (against NC1 and NC2 domains of C7) and indirect immunofluorescence (IIF) at W2, W4, M1, M3, M6 and M12 post-injections V.
Detection of T-cell responses to the full length C7 by enzymelinked immunosorbent spot (ELISPOT) assay at W4, M6 and M12 post-injections. Sample Size 5-10 patients
Summary of eligibility criteria
Inclusion criteria
1. Clinical and genetic diagnosis of RDEB with confirmed bi-allelic COL7A1 mutations. 2. A reduced number or morphologically abnormal anchoring fibrils confirmed by TEM. 3. At least 5x3cm of intact skin on the trunk and/or extremities that is suitable for cell injections. 4. Able to undergo local anesthesia. 5. Subjects aged ≥ 17years and able to give informed consent prior to the first study intervention.
Exclusion criteria
1. Subjects who received other investigational medicinal products within 6 months prior to enrolment into this study. 2. Past medical history of biopsy proven skin malignancy. 3. Subjects who have received immunotherapy including oral corticosteroids (Prednisolone >1mg/kg) for more than one week (intranasal and topical preparations are permitted) or chemotherapy within 60 days of enrolment into this study. 4. Known allergy to any of the constituents of the investigational medicinal product (IMP).
Subjects with BOTH:
• positive serum antibodies to C7 confirmed by ELISA and None.
Maximum duration of study participation
32 months (each patient will be followed up for a total of 12 months post-IMP injections and screening will take place up to 4 months prior to the intervention).
Version and date of protocol
Version 4.0, 01/MAR/2016
Production of third-generation SIN LV encoding codon-optimized full-length COL7A1 cDNA. This was manufactured as described in Georgiadis et al. (2016) . months after treatment, two ~6 mm shave skin biopsies were obtained from the left upper arm, one from the injected skin and one from the non-injected skin (as control)
~2 cm away from the injected skin. The non-injected skin biopsy was obtained before the injected skin biopsy using a separate biopsy kit in order to avoid cross-contamination. Both biopsies were further sectioned for IF, TEM, qPCR and snapfrozen and archived for integration site analysis in the event of serious adverse reactions.
Isolation and propagation of fibroblasts. The bottle containing the skin sample was cleaned by wiping with 70% ethanol and then transferred to a clean production room. The skin biopsy was washed with PBS and immersed in a tube containing 5mL
of neutral protease NB (1 unit /ml); and incubated at 37°C for 3 hrs. Three hours later, the tissue was transferred into a petri-dish and the epidermis was peeled off from the dermis using sterile forceps. The remaining dermis was cut into small pieces (about 1 mm 2 ) and transferred into a fresh tube containing 5mL of collagenase NB6 (0.45 units/ml), and incubated at 37°C for 2.5 hrs. The tissue/cells were re-suspended in PBS and pipetted up and down several times to obtain a homogeneous single cell
suspension. An equal volume of culture media was then added into the tube to neutralize the digestion solution. The cell suspension was centrifuged to pellet the cells, re-suspended in 3ml culture media and seeded in a T25 cell culture flask. Note:
the newly seeded cells were incubated for at least 3 days without disturbing. The media was changed 3 to 4 days after seeding. After this point, the media was changed twice a week.
Gene Engineering. Once fibroblasts reached confluence, cells were trypsinized and seeded in a 24-well cell culture plate 24 hrs prior to the transduction with LV-PGKcoCOL7A1 viral vector. In total 10 to 11 wells were seeded with the cells (1x10 Release of the IMP. The release was done in two stages, pre-release and final release. Pre-release. Pre-release required quality assurance (QA) and a qualified person (QP) checking all relevant documents including sterility tests, the IMP specificity and any deviations and file notes generated during the production period meet GMP requirements and have been completed and authorized.
Final release. This procedure was performed on the day, when the IMP was delivered to the hospital for the patient. The QP checked all documents for QA and Batch Manufacturing Record (BMR), in particular the gram staining result, liquid nitrogen temperature monitor recordings and release criteria based on the product specification (Supplemental Table 2 ). Once the QP was satisfied the production results meet QA, the following certificates were issued: a batch release certificate, a certificate Three days after transduction, cells were harvested and copies of HIV Psi packaging element (Psi) encoded by the vector were determined by quantitative polymerase chain reaction (qPCR). Qualified plasmid standards encoding Psi and human albumin sequences were used in qPCR (Supplemental Table 3 ). Transduction efficiency was determined at week-4 post-transduction.
Supplemental Table 3. Details of primers used for vector copy number (VCN) RT-qPCR.
C7 expression using flow cytometry. Cells (~0. rpm for 10 mins to pellet the insoluble cell debris at 4 0 C. The total protein concentration in the supernatant was determined using Bio-Rad protein assay kit (Hertfordshire, UK).
Samples from cell lysate were further diluted in 5x sample buffer containing 100 mmol/L dithiothreitol, 10% sodium dodecyl sulphate, 30% glycerol, 0.001% bromophenol blue, and 0.5 mmol/L Tris-HCl pH6.8. Equal quantities of total protein were loaded in 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred to polyvinylidene fluoride membranes and incubated with C7 antibody overnight at RT with shaking. Next day membranes were washed and further incubated with mouse anti-rabbit secondary antibody conjugated with HRP (Sigma-Aldrich, UK) and signals were detected using the ECLplus system (GE Healthcare, UK). The tube containing the filtrate was discarded. 500 l of Buffer AW2 was carefully added to the QIAamp Mini spin column without wetting the rim. With the cap closed, the mixture was centrifuged at full speed: 20,000 x g (14,000 rpm) for 3 min. The
Immunocytochemistry (ICC)
QIAamp Mini spin column was placed in a new 2 ml collection tube and centrifuged at full speed for 1 min. The old collection tube with the filtrate was discarded. The QIAamp
Mini spin column was placed in a clean 1.5 ml microcentrifuge tube and 200 l Buffer AE carefully added before incubation at room temperature for 1 min followed by centrifugation at 6000 x g (8000 rpm) for 1 min. The last step was repeated and the purified DNA was eluted in Buffer AE and placed at -20C.
Real-time quantification of vector copy number (VCN). VCN was determined by
real-time quantitative PCR using 100ng of DNA as a template for probe/primers specific to the PSI sequence of the lentivirus backbone and Human Albumin, used to quantify genomic DNA for normalization. A reference standard was obtained from serially diluted HT1080 fibrosarcoma cell line carrying one copy of integrated LV as detected and quantified by Southern blot. All reactions used Universal Master Mix (Applied Biosystems) and were run default conditions in the CFX96 Touch Real-Time PCR Detection System (Bio RAD). The data was analyzed using CFX Manager Software (Bio RAD).
Supplemental Figures and Figure Legends
Supplemental Figure 1 . LENTICOL-F trial timeline. An illustration of the schedule of visits for RDEB subjects on the trial. Each injection consists of 1.14- 
